Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402)
Phase 1
- Conditions
- Advanced stage IIIB/IV non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000014560
- Lead Sponsor
- Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) Symptomatic brain metastasis. 2) Current history of hemoptysis. 3) History of hypersensitivity for therapeutic agent or albumin products 4) With grade2 or more neuropathy 5) Uncontrolled ascites, pleural effusion or cardiac effusion. 6) Within 2 weeks after palliative radiotherapy 7) Within 4 weeks after operation 8) Active double malignancies 9) Fever over 38C 10) serious medical complications 11) Receiving anticoagulant drug (325mg and less aspirin is possible) 12) Pregnancy, breastfeeding or suspected of being pregnant 13) HBs positive patient 14) Others judged by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method